BIO-Europe Spring® 2014: Are big biotechs the better dealmakers?
In deciding whether to partner with pharma or big biotech, which one is the better dealmaker? A few key factors to consider when making this decision include: cash; the probability of technical success, or PTS; value creation; and liquidity. According to James Sabry of Genentech, the most important consideration is the PTS. Listen in as the panelists weigh the pros and cons of pharma vs. big biotech, and how to find the right strategic fit. For more information on BIO-Europe Spring, visit our webpage: http://www.ebdgroup.com/bes/index.php Please view the rest of the video at http://www.partnering360.com/insight/showroom/id/471